Le Lézard
Classified in: Health, Business
Subjects: CXP, MAT

Abingdon Dispensary Rev Canna Hosts Grand Opening


ABINGDON, Md., March 10, 2020 /PRNewswire/ -- Rev Canna, a new medical cannabis dispensary in Abingdon, Maryland, invites residents of Harford County and neighboring communities to a ribbon-cutting ceremony and other festivities on March 10. Local cannabis cultivators will be on hand to educate patients on how to best use cannabis to treat their conditions.

Rev Canna offers a carefully curated menu of flower, extracts, topicals, edibles, vapes, and other cannabis products from top Maryland cultivators, including Cresco, SunMed, Rhythm, MPX, Curio Wellness, Kind Therapeutics, Harvest, and Grassroots. Representatives from these brands will be available to answer questions about their products. The Maryland-based mobile espresso bar Park and Perk Café will offer coffee and snacks, while the lifestyle brand Crabcakes and Cannabis will offer swag that celebrates Maryland-state pride.

The ceremony will be held outside the dispensary at 12 pm ET. Rev Canna is located at 3111 Emmorton Road. Rev Canna's Owner Tara Brown and Manager Mark de Souza, who is also the CEO of Chicago-based, multi-state cannabis company Revolution Global, will cut the ribbon.

"Rev Canna is thrilled to be joining Maryland's legal cannabis industry, offering patients the highest-quality, responsibly-grown products," said de Souza. "Our products help patients live happier, healthier lives while managing chronic conditions, pain, and the side effects of chemo. We have received wonderful support in Abingdon already and look forward to officially introducing ourselves to the community today."

Maryland's medical cannabis industry has thrived since its legalization in December 2017. Today there are nearly 90 dispensaries, more than 1,000 medical providers licensed to prescribe, and more than 50,000 patients statewide. Rev Canna is the first dispensary to open in the Abingdon area.

Maryland residents who are interested in applying for a medical cannabis card can learn more at Rev Canna or the MMCC website.

About Rev Canna
Rev Canna is a medical dispensary located in Abingdon, Maryland. Since 2020, Rev Canna has offered extracts, topicals, edibles, vapes, and pre-roll products to patients in the state. We offer the highest quality cannabis products with a comfortable, safe environment for all patients. The dispensary stocks products from 13 cultivators statewide. For more information, visit: https://www.revcannamd.com/

Media Contact:
Emily Seeley
[email protected] 
(415) 517?7507

SOURCE Rev Canna


These press releases may also interest you

at 07:55
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...

at 07:35
Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31, a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share Related to Acquired IPR&D and...



News published on and distributed by: